The impact of reference-pricing systems in Europe: a literature review and case studies

References

• Ioannides-Demos L, Ibrahim J, McNeil J. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilization and health outcomes. Pharmacoeconomics20(9), 577–591 (2002).
   PubMed Web of Science ®Google Scholar
• Simoens S, De Coster S. Sustaining Generic Medicines Markets in Europe. KU Leuven, Leuven, Belgium (2006).
   Google Scholar
• Galizzi MM, Ghislandi S, Miraldo M. Effects of reference pricing in pharmaceutical markets: a review. Pharmacoeconomics29(1), 17–33 (2011).
   PubMed Web of Science ®Google Scholar
• Schneeweiss S. Reference drug programs: effectiveness and policy implications. Health Policy81, 17–28 (2007).
   PubMed Web of Science ®Google Scholar
• European Generic Medicines Association. 2008 Market Review. Brussels, Belgium (2008).
   Google Scholar
• Danzon P. Reference Pricing: Theory and Evidence. The Wharton School, University of Pennsylvania, PA, USA (2001).
   Google Scholar
• IMS Health. MIDAS Database. IMS Health, London, UK (2008).
   Google Scholar
• Stargardt T. The impact of reference pricing on the switching behaviour and healthcare utilization: the case of statins in Germany. Eur. J. Health Econ.11, 267–277 (2010).
   PubMed Web of Science ®Google Scholar
• Simoens S, De Bruyn K, Bogaert M, Laekeman G. Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics23(8), 755–766 (2005).
   PubMed Web of Science ®Google Scholar
• Klok RM, Boersma C, Oosterhuis I et al. Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands. Aliment. Pharmacol. Ther.23, 1595–1600 (2006).
   PubMedGoogle Scholar
• College voor zorgverzekeringen. GIP Database. CVZ, Diemen, The Netherlands (2011).
   Google Scholar
• Garattini L, Ghislandi S. Off-patent drugs in Italy. A short-sighted view? Eur. J. Health Econ.7, 79–83 (2006).
   PubMedGoogle Scholar
• Puig-Junoy J. The impact of generic reference pricing interventions in the statin market. Health Policy84, 14–29 (2007).
   PubMed Web of Science ®Google Scholar
• Ubeda A, Cardo E, Sellés N, Broseta R, Trillo JL, Fernández-Llimós F. Antidepressant utilization in primary care in a Spanish region. Impact of generic and reference-based pricing policy (2000–2004). Soc. Psychiatry Psychiatr. Epidemiol.42, 181–188 (2007).
   PubMedGoogle Scholar
• Koopmanshap M, Rutten F. The drug budget silo mentality: the Dutch case. Value Health6(1), 46–51 (2003).
   Google Scholar
• Ghislandi S, Krulichova I, Garattini L. Pharmaceutical policy in Italy: towards a structural change? Health Policy72, 53–63 (2005).
   PubMed Web of Science ®Google Scholar
• Brekke K, Grasdal A, Holmås TH. Regulation and pricing of pharmaceuticals: reference pricing of price cap regulation? Eur. Econ. Rev.53, 170–185 (2009).
   Web of Science ®Google Scholar
• Pavcnik N. Do pharmaceutical prices respond to potential patient out-of-pockets expenses? Rand J. Econ.33(3), 469–487 (2002).
   PubMed Web of Science ®Google Scholar
• Augurzky B, Göhlmann S, Gress S, Wasem J. Effects of the German reference drug program on ex-factory prices of prescription drugs: a panel data approach. Health Econ.18, 421–436 (2009).
   PubMedGoogle Scholar
• Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy44, 73–85 (1998).
   PubMed Web of Science ®Google Scholar
• Kaló Z, Muszbek N, Bodrogi J, Bidló J. Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence. Health Policy80, 402–412 (2007).
   PubMed Web of Science ®Google Scholar
• Kanavos P, Costa-Font J, Seeley E. Competition in off-patent drug markets: issues, regulation and evidence. Econom. Policy23(55), 499–544 (2008).
   Google Scholar
• Andersson K, Petzold M, Sonesson C, Lönnroth K, Carlsten A. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditure? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986–2002. Health Policy79, 231–243 (2006).
   PubMed Web of Science ®Google Scholar
• Danzon P, Ketcham J. Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, The Netherlands and New Zealand. National Bureau of Economic Research, Cambridge, MA, USA (2004).
   Google Scholar
• Puig-Junoy J, Moreno-Torres I. Do generic firms and the Spanish public purchaser respond to consumer price differences of generics under reference pricing? Health Policy98, 186–194 (2010).
   PubMedGoogle Scholar
• López-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy54, 87–123 (2000).
   PubMed Web of Science ®Google Scholar
• Håkonsen H, Horn AM, Toverud E-L. Price control as a strategy for pharmaceutical cost containment – what has been achieved in Norway in the period 1994–2004? Health Policy90, 277–285 (2009).
   PubMed Web of Science ®Google Scholar
• Mestre-Ferrandiz J. Reference prices and generic medicines: what can we expect? J. Gen. Med.1(1), 31–38 (2003).
   Google Scholar
• Espin J, Rovira J. Analysis of Differences and Commonalities in Pricing and Reimbursement Systems in Europe. Andalusian School of Public Health, Granada, Spain (2007).
   Google Scholar
• Grootendorst P, Dolovich L, Holbrook A, Levy A, O’Brien B. The Impact of Reference Pricing of Cardiovascular Drugs on Healthcare Costs and Health Outcomes: Evidence from British Columbia. Volume 2: Technical Report. Social and Economic Dimensions of an Aging Population Research Papers 71, McMaster University, Ontario, Canada (2002).
   Google Scholar
• Schneeweiss S, Walker A, Glynn R, Maclure M, Dormuth C, Soumerai S. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N. Engl. J. Med.346(11), 822–829 (2002).
   PubMed Web of Science ®Google Scholar
• Schneeweiss S, Soumerai S, Maclure M, Dormuth C, Walker A, Glynn R. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin. Pharmacol. Ther.74(4), 388–400 (2003).
   PubMedGoogle Scholar
• Dylst P, Simoens S. Generic medicine pricing policies in Europe: current status and impact. Pharmaceuticals3, 471–481 (2010).
   Google Scholar
• Charles River Associates. Innovation in the Pharmaceutical Sector. European Commission, Brussels, Belgium (2004).
   Google Scholar
• Annemans L, Arickx F, Belle O et al. A call to make valuable innovative medicines available in the European Union. Background report for the ministerial conference ‘Innovation and solidarity on pharmaceuticals’. RIZIV/INAMI, Brussels, Belgium (2010).
   Google Scholar
• Rutten F, Vulto A. The social value of innovation. Eur. J. Hosp. Pharm. Prac.16(3), 70–73 (2010).
   Google Scholar
• Wettermark B, Godman B, Eriksson C et al. [Introduction of new drugs in European health systems]. Gesundheit Gesellschaft Wissenschaft3, 24–34 (2010).
   Google Scholar